Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.65 |
| ▸ | RAB9A | P51151 | 7/20 | 0.65 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1990363 | 0.83 | NPC1 (0.69) | NPC1RAB9AEPHX2ALDH1A1HDAC3 | |
| SCHEMBL295136 | 0.83 | NPC1 (0.69) | NPC1RAB9AEPHX2ALDH1A1HDAC3 | |
| SCHEMBL28333508 | 0.82 | RAB9A (0.46) | NPC1RAB9APARP10ALDH1A1HDAC3 | |
| SCHEMBL693305 | 0.82 | NPC1 (0.67) | NPC1RAB9AEPHX2PARP10ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28989899 | 0.82 | NPC1 (0.67) | NPC1RAB9AEPHX2ALDH1A1HDAC3 | |
| Hydrogen Sulfide SCHEMBL5919025 | 0.82 | NPC1 (0.67) | NPC1RAB9AEPHX2ALDH1A1HDAC3 | |
| SCHEMBL680273 | 0.80 | NPC1 (0.65) | NPC1RAB9AEPHX2ALDH1A1 | |
| SCHEMBL6509893 | 0.80 | NPC1 (0.65) | NPC1RAB9AEPHX2ALDH1A1HDAC3 | |
| SCHEMBL14852000 | 0.80 | NPC1 (0.65) | NPC1RAB9AEPHX2ALDH1A1HDAC3 | |
| SCHEMBL5212482 | 0.80 | NPC1 (0.65) | NPC1RAB9AEPHX2ALDH1A1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1989188-B1 | THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2015-07-22 | — | — | EP | claimed |
| EP-2562168-B1 | THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2014-04-16 | — | — | EP | claimed |
| US-20140038945-A1 | PIPERAZINE PDE4 INHIBITORS AND USES THEREOF | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2014-02-06 | — | — | US | claimed |
| EP-2643000-A2 | THERAPEUTIC PIPERAZINES | Dart Neuroscience (Cayman) Ltd (KY) | 2013-10-02 | — | — | EP | claimed |
| US-8501745-B2 | Piperazine PDE4 inhibitors and uses thereof | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-08-06 | — | — | US | claimed |
| EP-2562168-A1 | Therapeutic piperazines as PDE4 inhibitors | Helicon Therapeutics, Inc. (US) | 2013-02-27 | — | — | EP | claimed |
| US-8338405-B2 | Therapeutic piperazines | DART NEUROSCIENCE LLC (US) | 2012-12-25 | — | — | US | claimed |
| WO-2012040258-A2 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. (US) | 2012-03-29 | — | — | WO | claimed |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-03-17 | — | — | US | claimed |
| US-20110065688-A1 | THERAPEUTIC PIPERAZINES | DART NEUROSCIENCE LLC | 2011-03-17 | — | — | US | claimed |
| US-20110065689-A1 | THERAPEUTIC PIPERAZINES | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-03-17 | — | — | US | claimed |
| EP-1989188-A1 | THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS | Helicon Therapeutics, Inc. (US) | 2008-11-12 | — | — | EP | claimed |
| WO-2007100852-A1 | THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS | HELICON THERAPEUTICS, INC. (US) | 2007-09-07 | — | — | WO | claimed |
| US-20070203124-A1 | Therapeutic Piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2007-08-30 | — | — | US | claimed |
| US-4861793-A | D-nor-7-ergoline derivatives having anti-Parkinson and antipsychosis activity and pharmaceutical compositions containing them | FARMITALIA CARLO ERBA, S.P.A (IT) | 1989-08-29 | — | — | US | claimed |
| EP-0240986-A2 | D-Nor-7-ergoline derivatives, process for preparing them, pharmaceutical composition and use | FARMITALIA CARLO ERBA S.r.l. (IT) | 1987-10-14 | — | — | EP | claimed |
| US-9624200-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-04-18 | — | — | US | disclosed |
| EP-1989188-B1 | THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2015-07-22 | — | — | EP | disclosed |
| US-4861793-A | D-nor-7-ergoline derivatives having anti-Parkinson and antipsychosis activity and pharmaceutical compositions containing them | FARMITALIA CARLO ERBA, S.P.A (IT) | 1989-08-29 | — | — | US | disclosed |
| EP-0240986-A2 | D-Nor-7-ergoline derivatives, process for preparing them, pharmaceutical composition and use | FARMITALIA CARLO ERBA S.r.l. (IT) | 1987-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203124-A1 | Therapeutic Piperazines | PDE4A, PDE4B, PDE12 | NPC1 1753/4885RAB9A 1819/4885EPHX2 1277/4885 |
| US-20110065688-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE12 | NPC1 1753/4885RAB9A 1819/4885EPHX2 1277/4885 |
| US-20110065689-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE12 | NPC1 1753/4885RAB9A 1819/4885EPHX2 1277/4885 |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | NPC1 1880/4885RAB9A 1524/4885EPHX2 1311/4885 |
| US-20140038945-A1 | PIPERAZINE PDE4 INHIBITORS AND USES THEREOF | PDE4A, PDE12, PDE4B | NPC1 2855/4885RAB9A 1888/4885EPHX2 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.